No Data
No Data
CARSGEN-B: INTERIM REPORT 2024
Koji Pharmaceutical - B (02171) fell by 59.60%, now reported at 2.69 yuan, hitting a 52-week low.
As of 11:46, Keji Pharmaceutical - B (02171) fell 59.60% compared to the previous closing price, now at 2.690 yuan, hitting a 52-week low; volume of 3.6526 million shares, with a turnover of 9.8273 million Hong Kong dollars.
CARsgen Therapeutics Holdings Limited's (HKG:2171) Stock Price Dropped 26% Last Week; Individual Investors Would Not Be Happy
CARsgen Announces 2024 Interim Results
CARsgen Therapeutics Holdings Books Narrower Attributable Loss in H1
Kesi Pharmaceuticals releases 2024 mid-term performance.
Shanghai, August 29, 2024 /PRNewswire/ -- Koji Pharmaceutical (Stock Code: 2171.HK), a company mainly focused on innovative CAR-T cell therapy for the treatment of hematologic malignancies and solid tumors, has released its 2024 interim performance highlights. Performance Highlights Quick Glance: Saicaize approved by the National Medical Products Administration for listing Completion of patient enrollment for the confirmatory Phase II trial of Shurijiolunsa injection (CT041) in China Active progress in multiple solid tumor CAR-T adjuvant therapy studies Clinical data of Shurijiolunsa injection, Saicaize, and CT071 presented at academic conferences.
No Data
No Data